ITMCTR2000004184RecruitingPhase 1
Clinical effects of Xingxiao Pill in the treatment of cancer
Dongfang Hospital, Beijing University of Chinese Medicine0 sitesStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional study
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1) Patients will be diagnosed as malignant tumors with cytological or histopathological diagnosis , including respiratory tract tumors, gastrointestinal tumors and reproductive system tumors;
- •2) Patients who have received chemotherapy in the past 1 month;
- •3) Aged >= 18 years;
- •4) Eastern Cooperative Oncology Group (ECOG) score <= 2 and estimated survival time > 1 month;
- •5) Have certain reading ability;
- •6) Voluntarily agree to participate in this study and sign the informed consent.
Exclusion Criteria
- •1) Hyperthermia occurs within two weeks with a body temperature of more than 38 degrees C, or there is obvious active infection;
- •2) Significant cardiovascular abnormalities (e.g., myocardial infarction, superior vena cava syndrome, grade 2 or above heart disease or uncontrolled hypertension before enrollment (systolic blood pressure over 160 mmHg or diastolic blood pressure over 100mmHg);
- •3) Serum bilirubin is 1.5 times higher than the upper limit of the reference range of normal value;
- •4) The serum myoliver is 1.5 times higher than the upper limit of the reference range of normal value or myoliver clearance rate < 50 ml/min;
- •5) ALT or AST > in the absence of liver metastasis; 2.5 times the upper limit of the normal value, or 5 times the upper limit of the reference range of ALT or AST in the case of liver metastasis;
- •6) Pregnant or lactating women;
- •7) Persons with mental illness or intellectual or language impairment;
- •8) Patients who are known to be allergic to the components used in the study;
- •9) Patients who are participating in other drug trials within the past month or so;
Investigators
Similar Trials
Recruiting
Not Applicable
Clinical Efficacy Evaluation of Qingzhixiaoyan Decoction in the Treatment of the Hyperlipidemia Caused by Aromatase Inhibitor for the Postmenopausal Breast CancerBreast CancerITMCTR2100004919Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine
Not yet recruiting
Phase 1
Efficacy and safety of Xin-Li-Fang in the treatment of chronic heart failure:A Randomized, double-blind, placebo-controlled studyChronic Heart FailureITMCTR2200005855The Second Affiliated Hospital of Guangzhou University of Chinese Medicine(Guangdong Provincial of Chinese Medicine)
Recruiting
Not Applicable
Clinical research of Xinglou Chengqi Decoction on improving post-stroke cognitive impairment due to phlegm heat and viscera excess syndrome based on brain-gut interactioPost-stroke Cognitive ImpairmentITMCTR2100004688Wenzhou Integrated Traditional Chinese and Western Medicine Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine
Not yet recruiting
Phase 4
Clinical Study of Tongmai Yangxin Pill in Treating Slow Arrhythmia (Qi-Yin Deficiency Syndrome)ITMCTR1900002578The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Recruiting
Phase 4
Clinical Study for Tongmai Yangxin Pill in Treating Premature Atrial Contraction With Qi and Yin Deficiency SyndromePremature atrial contractionITMCTR1900002579The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
